Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 10,101–10,200 of 15,747
Teefey, S. A., Middleton, W. D., Turner, J. S., Ellebedy, A. H., Suessen, T., Wallendorf, M., O’Halloran, J. A., & Presti, R. M. (2022) · Journal of Ultrasound in Medicine · doi:10.1002/jum.15973 · Cited by 4
“3% of participants.(3) The Centers for Disease Control reported vaccine-induced axillary lymphadenopathy after administration of the Moderna vaccine in 16.”
BackgroundLi, J., Li, X., Wang, E., Yang, J.-Y., Li, J., Huang, C., Zhang, Y., & Chen, K. (2022) · Vaccines · doi:10.3390/vaccines10122111 · Cited by 6
Majzoub, R. A., Alrofaie, O. H., Almotreb, L. K., Alateeq, S. K., & obaid, F. B. (2023) · Cureus · doi:10.7759/cureus.48776 · Cited by 5
“In clinical trials with children and adolescents, the vaccine's effectiveness was better than 90% [5].”
BackgroundTaubner, B., Peredo-Wende, R., Ramani, A., Singh, G., Strle, K., & Cady, N. C. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00890-21 · Cited by 5
“—Pfizer-BioNTech (13), Moderna (14), and single-dose Johnson & Johnson (15).”
BackgroundXiong, Z., Xia, Y., Xue, L., & Lei, J. (2025) · Bulletin of Mathematical Biology · doi:10.1007/s11538-025-01459-5 · Cited by 6
Romeo, V., Stanzione, A., D’Auria, D., et al. (2022) · Journal of Ultrasound · doi:10.1007/s40477-022-00674-3 · Cited by 4
Güven, S. C., Karakaş, Ö., Atalar, E., Konak, H. E., Dağlı, P. A., Erdoğan, E. K., Armağan, B., Gök, K., Doğan, İ., Maraş, Y., et al. (2022) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14349 · Cited by 3
Liu, X., Zhu, L., Lu, T., Liu, X., Jiao, D., Tang, X., Chen, J., Chen, Y., Yu, W., & Chen, Q. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.726491 · Cited by 4
McGrath, J., O’Doherty, L., Conlon, N. P., Dunne, J., Brady, G., Ibrahim, A., McCormack, W. J., Walsh, C., Domegan, L. M., Walsh, S., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1245464 · Cited by 4
Serna, Á., Navarro, V., Jiménez, M., Iraola‐Truchuelo, J., Bosch, M., García-Herce, C., Falcó-Roget, A., Albasanz‐Puig, A., Ruíz-Camps, I., Andrés, C., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015406 · Cited by 5
Rossier, L., Décosterd, N., Matter, C., Staudenmann, D., Moser, A., Egger, B., & Seibold, F. (2024) · Annals of Medicine · doi:10.1080/07853890.2023.2295979 · Cited by 4
Kolandai‐Matchett, K., Milne, B. J., von Randow, M., Bullen, C., Marsh, S., & Crump, J. A. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.091 · Cited by 5
Zhang, Q., Wang, M., Han, C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.19.517879 · Cited by 4
“convenient large-scale 50 production (12, 13); 4.”
Lee, C. M., Choe, P. G., Kang, C. K., Lee, E., Song, K., Bang, J. H., Kim, E. S., Kim, H. B., Kim, N. J., Kim, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1106664 · Cited by 4
Side Effects of COVID-19 Vaccines in Patients with Inflammatory Bowel Disease in Japan
Miyazaki, H., Watanabe, D., Ito, Y., Okamoto, N., Tokunaga, E., Ku, Y., Ooi, M., Hoshi, N., & Kodama, Y. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07703-5 · Cited by 3
Pastorio, C., Zech, F., Noettger, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.13.488221 · Cited by 4
The anti-COVID-19 drug Paxlovid crosses biological barriers of the placenta and brain in rats
Lee, W.-H., Sun, C., Chang, C., Yang, M., & Tsai, T. (2024) · npj Viruses · doi:10.1038/s44298-023-00013-1 · Cited by 4
Adhikary, K., Paul, A., Madan, A., Islam, A., Ashique, S., & Ramzan, M. (2025) · Advances in immunology · doi:10.1016/bs.ai.2024.10.011 · Cited by 8
Cho, H., Lee, H. S., Kim, S. H., Shin, J., & Hwang, J. H. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e341 · Cited by 4
Kuan, A. S., Chen, S., Wang, Y.-F., & Wang, S. (2023) · Cephalalgia · doi:10.1177/03331024231208110 · Cited by 5
“…were also detected after booster dose of vaccine injection, which parallel the higher proportion of headache after booster dose of vaccine users reported here (proportion with increased headache days: 35.1% after booster dose > 29.6% after primary dose) and by published studies (3,6–8, 19, 20).”
BackgroundInfluentialAddetia, A., Schäfer, A., Sprouse, K. R., Valdez, A., Taylor, A., Navarro, M.-J., Brown, J. T., Leaf, E. M., Miranda, M. C., Walls, A. C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.11.652904 · Cited by 4
Strategic Planning of a Joint SARS-CoV-2 and Influenza Vaccination Campaign in the UK
Ibrahim, D. S., Kis, Z., Papathanasiou, M. M., Kontoravdi, C., Chachuat, B., & Shah, N. (2024) · Vaccines · doi:10.3390/vaccines12020158 · Cited by 4
Konstantopoulos, A. D., Dayton, L., & Latkin, C. A. (2023) · Psychology Health & Medicine · doi:10.1080/13548506.2023.2283401 · Cited by 9
“Although side effects can occur, the majority of individuals report only mild to moderate temporary effects (Polack et al., 2020).”
BackgroundAlmeida, B., Dias, T. R., Teixeira, A. L., Dias, F., & Medeiros, R. (2023) · Cancers · doi:10.3390/cancers15164017 · Cited by 4
Hoxha, A., Tomaselli, T., Minicuci, G. M., Dall’Acqua, J., Zardo, D., Simioni, P., & Naldi, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062376 · Cited by 4
Shayak, B., Sharma, M., & Mishra, A. K. (2021) · medRxiv · doi:10.1101/2021.02.22.21252241 · Cited by 4
Girl, P., Zwirglmaier, K., von Buttlar, H., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3963559 · Cited by 4
Tachycardia following Pfizer-BioNTech COVID-19 vaccine
Martins‐Filho, P. R. (2022) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2022.06.001 · Cited by 4
Recursive contact tracing in Reed–Frost epidemic models
Shivam, S., Bulchandani, V. B., & Sondhi, S. L. (2021) · Physical Biology · doi:10.1088/1478-3975/ac0fd1 · Cited by 3
Toxicologic Pathology Forum: mRNA Vaccine Safety–Separating Fact From Fiction
Sellers, R. S., & Dormitzer, P. R. (2024) · Toxicologic Pathology · doi:10.1177/01926233241278298 · Cited by 4
“8,69 Currently, the data suggest that the lipid component of the mRNA-LNP vaccine is largely responsible for reactogenicity as well as adjuvanticity (ability to enhance the immune response to the antigen), as administration of empty LNPs will result in robust innate immune responses similar to…”
BackgroundSelf-citationNgare, I., Tan, T. S., Toyoda, M., Kuwata, T., Takahama, S., Nakashima, E., Yamasaki, N., Motozono, C., Fujii, T., Minami, R., et al. (2024) · Viruses · doi:10.3390/v16040555 · Cited by 4
“The rollout of global COVID-19 vaccination raised concerns over the ability of people living with HIV (PLWH) to elicit optimal immune responses given their underrepresentation in preceding clinical trials [1,2].”
BackgroundDermatologists’ attitude towards psoriasis treatment during the COVID-19 pandemic
Torres, T., Pereira, M. M., Lopes, M. J. P., et al. (2021) · Drugs in Context · doi:10.7573/dic.2021-4-4 · Cited by 4
Lefeuvre, M., Kerneuzet, I., Darrieux, L., et al. (2022) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2022.02.001 · Cited by 4
“[1] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.”
Aziz, N., Safaruddin, A. D. A., Hamzah, N. A., Supadi, S. S., Zhou, Y., & Aziz, M. A. (2022) · Acta Biotheoretica · doi:10.1007/s10441-022-09453-3 · Cited by 5
Hwang, Y. H., Min, D., & Park, W. B. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2473795 · Cited by 4
Adamson, P. C., Pfeffer, M. A., Arboleda, V. A., Garner, O. B., Maurice, A. D. S., von Bredow, B., Flint, J., Kruglyak, L., & Currier, J. S. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab526 · Cited by 7
Rodríguez, J. L. G., Oprescu, A. M., Lezcano, S. M., Ramos, J., Romero‐Cabrera, J. L., de la Hoz, M. Á. A., & Estella, Á. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1437388 · Cited by 4
Barnes, S. J., Na, Y., Drainoni, M., Linas, B. P., Bosch, N. A., & Tamlyn, A. L. (2025) · PLoS ONE · doi:10.1371/journal.pone.0313530 · Cited by 6
Lee, M. X., Peng, S., Lee, A. R. Y. B., Wong, S. Y., Tay, R. Y. K., Li, J., Tariq, A., Goh, C. X. Y., Tan, Y. K., Tan, B. K. J., et al. (2023) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2022302 · Cited by 4
Tanaka, H., Mukai, J., Kushibiki, K., Mizushima, S., Maeda, K., Fujimoto, Y., Sawada, R., Oda, M., Okuda, H., Yamaki, M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.11.049 · Cited by 5
“The vaccine, administered in two doses 21 days apart, generally has mild side-effects, and has been shown to have 95 % efficacy in preventing COVID-19 between seven days to two months after the second dose, [2] but the efficacy decreases to 84 %, four to six months after the second dose.”
Backgroundde Zalán, C. M. C. S.-K. A., Bouwman, M. M. A., van Osch, F., Damoiseaux, J. G. M. C., der Snoek, M.-A. F.-V., Lunel, F. M. V., van Hunsel, F. P. A. M., & de Vries, J. (2023) · Vaccines · doi:10.3390/vaccines12010039 · Cited by 5
“One of several approved vaccines against COVID-19, BNT162b2 (Comirnaty ® ; BioNTech, Mainz, Germany) is a nucleoside-modified mRNA vaccine encapsulated in lipid nanoparticles, based on mRNA encoding the SARS-CoV-2 spike protein [6].”
BackgroundFu, Y., Wu, K., Wang, Z., Yang, H., Chen, Y., Wu, L., Yanagihara, R. T., Hedges, J. R., Wang, H., & Deng, Y. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.08.069 · Cited by 5
Long-Term Neutralizing Antibody Titers After BNT162b2 Vaccination in Hemodialysis Patients
Takazono, T., Tun, M. M. N., Funakoshi, S., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.06.008 · Cited by 4
Anti-SARS-CoV-2 (COVID-19) vaccination efficacy in patients with severe neuromuscular diseases
Damour, A., Delalande, P., Cordelières, F. P., Lafon, M., Faure, M., Ségovia-Kueny, S., Stalens, C., Mathis, S., Spinazzi, M., Violleau, M., et al. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2023.04.003 · Cited by 4
Kobayashi, M., Miyamoto, A., Watanabe, T., Sawa, K., Sato, K., Yamada, K., Yoshii, N., Yamada, K., Kawamoto, K., Uji, M., et al. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2022.12.011 · Cited by 4
Iqbal, T., Tan, S. S., Effendi-Tenang, I., Samsudin, A., Ling, K., Tan, W. Y., Ramasamy, S., & Fong, K. C. S. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1243055 · Cited by 6
“The Pfizer-BioNTech (BNT162b2) COVID-19 vaccine is a form of mRNA vaccine that encodes the viral spike protein of COVID-19 and is generally well tolerated in phase III clinical trials (Polack et al., 2020).”
BackgroundmRNA COVID-19 Vaccine for People with Kidney Failure: Hope but Prudence Warranted
Miskulin, D. C., & Combe, C. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04500421 · Cited by 4
Kurihara, C., Greco, D. B., Dhai, A., Saio, T., & Tsubaki, H. (2023) · Springer eBooks · doi:10.1007/978-981-99-6163-4_11 · Cited by 4
Estresse em universitários: conhecendo o efeito das atividades remotas no cotidiano pandêmico
Freires, L. A., Fernandes, S. C. S., Castro, A. M. F. D. M., de Oliveira, L. C., Torres, L. F. F., & Santos, E. F. (2023) · Revista Brasileira de Educação · doi:10.1590/s1413-24782023280006 · Cited by 7
Comparative Benefits and Risks Associated with Currently Authorized COVID-19 Vaccines
Albers, J. R., Brown, J. B., Charkowick, S. V., Ram, N., Klocksieben, F. A., & Kumar, A. (2022) · Vaccines · doi:10.3390/vaccines10122065 · Cited by 5
“First to emerge publicly, the clinical trial results from five major vaccines have been published outlining their efficacy and safety: Pfizer-BioNTech BNT162b2 mRNA vaccine [3], Moderna-US National Institute of Health (NIH) mRN-1273 vaccine [4], Johnson & Johnson (J&J) Ad26.”
BackgroundMethodThe Effects of COVID-19 Vaccines on Economic Activity
Deb, P., Furceri, D., Jiménez, D., Kothari, S., Ostry, J. D., & Tawk, N. (2021) · Zeitschrift für schweizerische Statistik und Volkswirtschaft/Schweizerische Zeitschrift für Volkswirtschaft und Statistik/Swiss journal of economics and statistics · doi:10.1186/s41937-021-00082-0 · Cited by 23
Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
Felices-Farias, J. M., Martínez-Martínez, J. F., & Guzmán‐Aroca, F. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2021.06.018 · Cited by 4
Тотолян, А. А., Смирнов, В. С., Krasnov, A. A., Ramsay, E. S., Dedkov, V. G., & Popova, A. Y. (2023) · Viruses · doi:10.3390/v15112181 · Cited by 8
(2023) · doi:10.20944/preprints202309.0131.v1 · Cited by 4
“[6] and Thomas et al. [7] have internal inconsistencies between the number of deaths reported in their flow charts and the number reported the text of the manuscript.”
InfluentialProgress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner?
Harper, J. L., Betts, M. R., Lichterfeld, M. D., Müller-Trutwin, M. C., Margolis, D. M., Bar, K. J., Li, J. Z., McCune, J. M., Lewin, S. R., Kulpa, D. A., et al. (2024) · Pathogens and Immunity · doi:10.20411/pai.v8i2.665 · Cited by 11
“A less durable alternative, the delivery of mRNA [189, 190] via lipid nanoparticles (LNPs), has been demonstrated as a safe, effective, and economical therapeutic option to temporarily induce transgene expression, as evidenced by the success of the SARS-CoV-2 mRNA vaccines [191, 192].”
BackgroundCOVID-19 vaccine efficacy data: solid enough to delay second dose?
Robertson, J. F. R., & Sewell, H. F. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01046-1 · Cited by 4
Oktay, E. Ö., Tuncay, S., Kaman, T., Karasakal, Ö. F., Özcan, Ö. Ö., SOYLAMIŞ, T., Karahan, M., & Konuk, M. (2021) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-2106-23 · Cited by 5
“5%, 79%, and 70% vaccine efficacy (Polack et al., 2020).”
InfluentialPremužić, V., Stevanović, R., Vilibić‐Čavlek, T., Sirovica, M., Stalman, S., Bogdanić, M., Zilic, D., Nakić, D., Santini-Dušević, D., Vojković, M., et al. (2023) · Antibodies · doi:10.3390/antib12020037 · Cited by 4
“Our results showed that the vaccination is effective in the prevention of more severe forms of COVID-19 in these chronic patients, but the serological response is still significantly lower when compared to healthy subjects [33,34].”
ResultYounes, S. N., Nicolai, E., Al‐Sadeq, D. W., Younes, N., Al-Dewik, N. I. E., Abou-Saleh, H., Halawa, B. Y. A., Eid, A. H., Pieri, M., Liu, N., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.08.009 · Cited by 4
Zhang, Y., Tian, C., Yu, X., Yu, G., Han, X., Wang, Y., Zhou, H., Zhang, S., Li, M., Yang, T., et al. (2024) · Vaccines · doi:10.3390/vaccines12121315 · Cited by 5
“Recent advances in mRNA technology for treating and preventing infectious diseases have sparked interest in using this platform to produce antibodies [27,28].”
Moser, L. J., Lisi, C., Gutberlet, M., Boccalini, S., Budde, R. P. J., Francone, M., Paar, M. H., Loewe, C., Muscogiuri, G., Natale, L., et al. (2025) · European Radiology · doi:10.1007/s00330-025-11464-w · Cited by 5
Cancer Neoantigen Vaccines Emerge Efficacious
Sultan, H., & Schreiber, R. D. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-071723-045853 · Cited by 5
Mead, M. N., Seneff, S., Rose, J., Wolfinger, R. D., Hulscher, N., & McCullough, P. A. (2024) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/w66wjg87 · Cited by 13
A case of hemophagocytic lymphohistiocytosis after BNT162b2 COVID-19 (Comirnaty®) vaccination
Shimada, Y., Nagaba, Y., Okawa, H., et al. (2022) · Medicine · doi:10.1097/md.0000000000031304 · Cited by 4
“However, they should not be used to diminish the well-documented safety profile of the mRNA vaccine against COVID-19, which has been widely administered and shows good immunogenicity, tolerance, and high efficacy in inducing immune responses against SARS-CoV-2.[2,3] In COVID-19 patients, secondary HLH and the cytokine…”
BackgroundEngineered strategies for enhancing mRNA vaccine stability in delivery and storage
Cerav, E. N., Yao, Z., & Sun, B. (2026) · Nanoscale · doi:10.1039/d5nr05189d · Cited by 6
How the Global COVID-19 Pandemic Brought Drug and Vaccine Development into the Public Mainstream
Witek, T. J. (2021) · Pharmaceutical Medicine · doi:10.1007/s40290-021-00402-y · Cited by 6
Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
Felices-Farias, J. M., Martínez-Martínez, J. F., & Guzmán‐Aroca, F. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.06.002 · Cited by 4
Impact of vaccination on COVID-19 severity during the second wave in Brunei Darussalam, 2021
Chong, C. F., Abdullah, M. S., Chong, P. L., Asli, R., Mani, B. I., Momin, N. R., Wong, J., Rahman, N. A., Tan, J. C., & Chong, V. H. (2024) · Western Pacific surveillance response journal · doi:10.5365/wpsar.2024.15.1.992 · Cited by 3
Isolated breast parenchymal changes following COVID-19 vaccine booster
Soeder, E., Toro-Pape, F. W., & Lampen-Sachar, K. (2022) · Radiology Case Reports · doi:10.1016/j.radcr.2022.08.094 · Cited by 4
“[3] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.”
Ahmed, N., Francis, M. E., Ahmed, N. T., Kelvin, A. A., & Pezacki, J. P. (2023) · Viruses · doi:10.3390/v15091921 · Cited by 4
“Fortunately, effective vaccine development and production rapidly evolved over the past year, aiding in curbing the spread of the virus globally [2,8].”
BackgroundHishida, E., Ono, Y., Oe, K., Imai, T., Yoshizawa, H., Nakaya, T., Kawata, H., Akimoto, T., Saitô, O., & Nagata, D. (2023) · Internal Medicine · doi:10.2169/internalmedicine.1631-23 · Cited by 4
“Several vaccines against SARS-CoV-2 have been developed to combat the COVID-19 pandemic, and clinical trials have confirmed their high efficacy and safety profile (1, 2).”
BackgroundRiemann, L., Weskamm, L. M., Mayer, L., Odak, I., Hammerschmidt, S. I., Sandrock, I., Friedrichsen, M., Ravens, I., Fuß, J., Hansen, G., et al. (2024) · European Journal of Immunology · doi:10.1002/eji.202451236 · Cited by 5
Huemer, F., Rinnerthaler, G., Jörg, B. S., Morre, P., Stegbuchner, B., Proksch, E., Fleimisch, S., Oberkofler, H., Kremser, I., Greil, R., et al. (2021) · GeroScience · doi:10.1007/s11357-021-00352-y · Cited by 5
Robbins, T., Kyrou, I., Clark, C. C. T., Sharma, K., Laird, S., Berry, L., Morgan, N., Patel, K., Sankar, S., & Randeva, H. S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18179378 · Cited by 5
“Approved COVID-19 vaccines now offer the promise of potentially reducing the rates of SARS-CoV-2 infection and severe COVID-19 [6,7], and are particularly important to healthcare staff [26].”
BackgroundKim, J., Jeong, J., Lee, C.-M., Lee, D.-W., Kang, C. K., Choe, P., Kim, N., Oh, M., Lee, C.-H., Park, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1028102 · Cited by 3
Bassi, J., Giannini, O., Silacci-Fregni, C., et al. (2021) · medRxiv · doi:10.1101/2021.10.05.21264054 · Cited by 4
Mokahal, A. E., Daher, H. B., Yamout, R., et al. (2023) · iGIE · doi:10.1016/j.igie.2023.07.014 · Cited by 4
“22 Although this risk has since been decreased by the advent of vaccines, 23,24 1 group at a higher risk of contracting the virus are those involved in aerosol-generating procedures.”
Schneider, K. A., Obama, H. C. J. T., Yousif, N. A. M., & Ngougoue, P. M. N. (2023) · PLoS ONE · doi:10.1371/journal.pone.0277505 · Cited by 6
“Nevertheless, clinical studies proved the effectiveness of vaccines to protect from severe forms of the disease and hence mortality [14, 15].”
BackgroundO’Reilly, S. R., Kenny, G., Alrawahneh, T., Francois, N., Gu, L., Angeliadis, M., d’Autume, V. D. M., Leon, A. G., Feeney, E. R., Yousif, O., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294262 · Cited by 4
In Vivo miRNA Decoy Screen Reveals miR-124a as a Suppressor of Melanoma Metastasis
Moubarak, R. S., Koetz‐Ploch, L., Mullokandov, G., Gaziel, A., de Pablos-Aragoneses, A., Argibay, D., Kleffman, K., Sokolova, E., Berwick, M., Thomas, N. E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.852952 · Cited by 4
Isogawa, M., Onodera, T., Ainai, A., Kotaki, R., Kanno, T., Saito, S., Tobiume, M., Tokunaga, K., Hara, M., Hirota, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-00054-x · Cited by 5
“…antibodies serve as the first line of defense and are shown to correlate with the vaccine effectiveness (VE) within 3 months after the booster when high antibody titers are maintained, providing the basis for using the neutralizing antibody titers as the immune correlate of protection 11–14 .”
Lee, J. K., & Shin, O. S. (2022) · Journal of Yeungnam Medical Science · doi:10.12701/jyms.2021.01669 · Cited by 5
“to maintain a prefusion conformation [30,31].”
Lustig, Y., Sapir, E., Regev-Yochay, G., Cohen, C., Fluss, R., Olmer, L., Indenbaum, V., Mandelboim, M., Doolman, R., Amit, S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3790408 · Cited by 4
Lillie, P. J., O’Brien, P. E., Lawtie, M., Jessop, S., Easom, N. J. W., & Patmore, R. D. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab351 · Cited by 4
Effect of COVID-19 vaccination coverage on transmission and mortality during Omicron dominance
Ogbodo, S. C., Damba, J. J., Olaoye, O. C., Ofili, D.-F. C., & Ngwu, A. A. (2025) · Academia Medicine · doi:10.20935/acadmed7536 · Cited by 4
(2022) · doi:10.1101/2022.01.07.22268883 · Cited by 4
“4% were female, and the median age was 25 (2-28) year-olds.”
BackgroundA synthetic system for RNA-responsive pyroptosis based on type III-E CRISPR nuclease-protease
He, M., Wang, W., Zhou, H., Liu, C., Zhao, C., Li, J. B., Han, Y., Qin, Y., & Chen, M. (2026) · Nature Communications · doi:10.1038/s41467-026-69179-5 · Cited by 5
Lakhanpal, M., Sarkar, D., Kumar, R., et al. (2022) · Anesthesia Essays and Researches · doi:10.4103/aer.aer_55_22 · Cited by 4
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.